NCT05774418View on ClinicalTrials.gov

Evaluation of the Impact of the Anti COVID-19 Vaccination Campaign Addressed to the Employees of an Italian Hospital.

CompletedOBSERVATIONAL

Enrollment

6,649

Participants

Timeline

Start Date

December 28, 2020

Primary Completion Date

March 31, 2021

Study Completion Date

March 31, 2021

Conditions

COVID-19

Interventions

BIOLOGICAL

BNT162b2 COVID-19 Vaccine

BNT162b2 is a vaccine for preventing coronavirus disease 2019 (COVID-19) in people from the age of 18 years. BNT162b2 contains tozinameran, a messenger RNA (mRNA) molecule with instructions for producing a protein from the original strain of SARS-CoV-2, the virus that causes COVID-19. BNT162b2 is given as two injections, usually into the muscle of the upper arm, 3 weeks apart.

Trial Locations (1)

00168

"Fondazione Policlinico Universitario A. Gemelli IRCCS", Roma

All Listed Sponsors

lead

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

OTHER

NCT05774418 - Evaluation of the Impact of the Anti COVID-19 Vaccination Campaign Addressed to the Employees of an Italian Hospital. | Biotech Hunter | Biotech Hunter